Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 23, 2011

View Archived Issues

KAI Pharmaceuticals releases clinical data on KAI-4169

Bendamustine evaluated in anaplastic glioma

Promising preclinical data presented on GBR-401

Potential new biomarker for the diagnosis of giant cell arteritis

Plasma biomarker of small cell lung cancer identified

DNA polymerase eta levels predict oxaliplatin efficacy in esophageal cancer

Bafetinib as potential therapeutic for Parkinson's disease

Merck & Co. designs novel beta3-adrenoceptor agonists

New lysophospholipid S1P1 receptor modulators disclosed by Allergan

Phase III study of DiaPep277 in type 1 diabetes meets primary endpoint

Selecta Biosciences commences clinical trial of vaccine for smoking cessation

New steroidal lactones from M. crassissima disclosed by PharmaMar

Portola completes financing round

Pierre Fabre Medicament gains approval to market Joncia in Australia

Pfizer to acquire Excaliard Pharmaceuticals

Japanese researchers prepare novel Toll-like receptor antagonists

Compounds that modulate skeletal muscle contractility disclosed by Cytokinetics

Cara Therapeutics starts first clinical study of oral CR-845

Swissmedic approves Celgene's Revlimid

GLPG-0634 shows signs of efficacy and safety in phase II study

Trimel Pharmaceuticals provides update on CompleoTRT study

EMA committee recommends approval of new indication for Herceptin

Phase III study investigates CXA-201 and metronidazole for intra-abdominal infections

Celgene to discontinue study of treatment regimen for castration-resistant prostate cancer

Landmark study to evaluate regenerative stem cell strategy to treat MS

Milestone reached in PsychoGenics/Roche drug discovery collaboration

FDA accepts for review Regeneron's sBLA for Arcalyst

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...